In June of this year, Daniel Tumas of Gilead Sciences, Inc. spoke at the Institute of Medicine of the National Academies’ workshop, The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research. Tumas discussed the benefits of translational medicine to canine patients and how that, in turn, could help human patients in the future. He spoke of a molecule that Gilead Sciences developed for use in human patients, and that was discontinued due to unsuccessful results. However, the molecule proved to help fight cancer in canine companion animals, and was out-liscenced to VetDC. It became what we call, Tanovea™-CA1.
Take a look at his full presentation here: